These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37253969)

  • 1. The prevalence and burden of Rome IV bowel disorders of gut brain interaction in patients with non-alcoholic fatty liver disease: a cross-sectional study.
    Purssell H; Bennett L; Street O; Hanley KP; Hanley N; Vasant DH; Athwal VS
    Sci Rep; 2023 May; 13(1):8769. PubMed ID: 37253969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of disorders of gut-brain interaction in the Japanese population in the Rome Foundation Global Epidemiological Study.
    Fukudo S; Nakaya K; Muratsubaki T; Nakaya N; Hozawa A; Bangdiwala SI; Palsson OS; Sperber AD; Kanazawa M
    Neurogastroenterol Motil; 2023 Jun; 35(6):e14581. PubMed ID: 37093785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.
    Goodoory VC; Guthrie EA; Ng CE; Black CJ; Ford AC
    Aliment Pharmacol Ther; 2023 Feb; 57(3):323-334. PubMed ID: 36544055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of the Rome III and Rome IV criteria for diagnosis of irritable bowel syndrome in Indian and Bangladeshi communities and internal shifts in the diagnostic categories of bowel disorders of gut-brain interactions.
    Ghoshal UC; Rahman MM; Pratap N; Misra A; Sarker SA; Hasan M; Bangdiwala SI; Palsson OS; Sperber AD
    Neurogastroenterol Motil; 2023 Jun; 35(6):e14579. PubMed ID: 37010834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life.
    Sperber AD; Freud T; Aziz I; Palsson OS; Drossman DA; Dumitrascu DL; Fang X; Fukudo S; Ghoshal UC; Kellow J; Khatun R; Okeke E; Quigley EMM; Schmulson M; Simren M; Tack J; Whitehead WE; Whorwell P; Bangdiwala SI
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e945-e956. PubMed ID: 34052391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of Life and Bidirectional Gut-Brain Interactions in Irritable Bowel Syndrome From Adolescence to Adulthood.
    Sjölund J; Kull I; Bergström A; Ljótsson B; Törnblom H; Olén O; Simrén M
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):858-866.e6. PubMed ID: 37802270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease.
    Fairbrass KM; Selinger CP; Gracie DJ; Ford AC
    Neurogastroenterol Motil; 2022 May; 34(5):e14256. PubMed ID: 34472157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective.
    Wang YT; Lim HY; Tai D; Krishnamoorthy TL; Tan T; Barbier S; Thumboo J
    BMC Gastroenterol; 2012 Aug; 12():104. PubMed ID: 22873839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.
    Goodoory VC; Ng CE; Black CJ; Ford AC
    Aliment Pharmacol Ther; 2023 May; 57(10):1083-1092. PubMed ID: 36914979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and description of disorders of gut-brain interaction in Spain according to the results of the Rome Foundation Global Epidemiology Study.
    Flores-Arriaga J; Aso MC; Izagirre A; Sperber AD; Palsson OS; Bangdiwala SI; Lanas Á; Bujanda L; Lobo B; Alonso-Cotoner C; Sánchez-Pla Á; Santos J
    Neurogastroenterol Motil; 2023 Jun; 35(6):e14582. PubMed ID: 37010843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of disorders of Gut-Brain interaction in Israel: Results from the Rome Foundation global epidemiology study.
    Sperber AD; Freud T; Abu-Freha N; Shibli F; Brun R; Bangdiwala SI; Palsson OS; Dickman R
    Neurogastroenterol Motil; 2022 Aug; 34(8):e14323. PubMed ID: 35072332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Rome IV criteria on the prevalence of post-infection irritable bowel syndrome.
    Breen-Lyles M; Decuir M; Byale A; Smith K; Grover M
    Neurogastroenterol Motil; 2023 May; 35(5):e14532. PubMed ID: 36633303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidemiology and impact of disorders of gut-brain interaction in Canada: Results from the Rome Foundation Global Epidemiologic Study.
    Rodrigues DM; Poitras P; Day AG; Sperber AD; Palsson O; Bangdiwala SI; Vanner SJ
    Neurogastroenterol Motil; 2023 Jun; 35(6):e14585. PubMed ID: 36989173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden.
    Khasawneh M; Shaikh FA; Ng CE; Black CJ; Goodoory VC; Ford AC
    Neurogastroenterol Motil; 2024 Apr; 36(4):e14756. PubMed ID: 38321517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome.
    Sturkenboom R; Keszthelyi D; Brandts L; Weerts ZZRM; Snijkers JTW; Masclee AAM; Essers BAB
    Qual Life Res; 2022 Apr; 31(4):1209-1221. PubMed ID: 34546554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study].
    Maev IV; Okhlobystina OZ; Khalif IL; Andreev DN
    Ter Arkh; 2023 Feb; 95(1):38-51. PubMed ID: 37167114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.
    Oka P; Parr H; Barberio B; Black CJ; Savarino EV; Ford AC
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):908-917. PubMed ID: 32702295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are bowel symptoms and psychosocial features different in irritable bowel syndrome patients with abdominal discomfort compared to abdominal pain?
    Fang XC; Fan WJ; Drossman DD; Han SM; Ke MY
    World J Gastroenterol; 2022 Sep; 28(33):4861-4874. PubMed ID: 36156921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study.
    Vork L; Weerts ZZRM; Mujagic Z; Kruimel JW; Hesselink MAM; Muris JWM; Keszthelyi D; Jonkers DMAE; Masclee AAM
    Neurogastroenterol Motil; 2018 Feb; 30(2):. PubMed ID: 28804974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.